Top Cannabis Investment News, Member Posts, Cannabis Investment Daily Indices and more!

3yrs ago Cannabis harrisbricken Views: 506

-

The craze for hemp-derived cannabidiol (CBD) extends beyond the United States and into Europe. We’ve written a good amount on the difference between how the European Union (EU) regulates CBD in contrast to the United States, and link to a number of those posts at the bottom of this page. All of that may be put on hold soon as the EU weighs new laws for CBD products.

For some background, the European Foods Safety Authority (“EFSA”) previously classified CBD as a “novel food” ingredient. A “novel food” is “food that was not used for human consumption to a significant degree within the Union before 15 May 1997, irrespective of the dates of accession of the Member States to the Union.” Pursuant to EU regulations, anyone who wishes to sell food containing a “novel food” ingredient must first secure a license from the EFSA.

Guidance issued by the EU on a plethora of various cannabinoids suggested that foods containing hemp-derived cannabinoids (and not just CBD) were considered novel foods because there has been no demonstration that they were consumed prior to the 1997 date. If something is a novel food, then certain regulatory approvals are needed to advance it in the market. Needless to say, it’s a long process, but if you want to read more about it, see the first linked post at the bottom of this page.

In mid-July 2020, it was reported (see here and here) that the EU was halting novel food applications for foods containing CBD and is apparently considering designating such CBD-bearing foods as narcotics. And here we were thinking that the United States’ policy on CBD in foods was bizarre….

According to reports, the EU notified all of the approximately 50 CBD novel foods applicants and directed them to provide feedback as to whether the substances should be designated as narcotics. Notably, this only applies to naturally occurring CBD products and an EU spokesperson reportedly noted that applications for products bearing synthetically derived CBD may still proceed. Additionally, since this only covers novel foods, this may not have an effect on CBD in other kinds of products, such as cosmetics.

We imagine the EU’s most recent change of position will be met with intense pushback from applicants, and it’s been reported that the European Industrial Hemp Association has been lobbying hard against it. Only time will tell whether the EU tries to label or regulate CBD gummies as narcotics, but in the meantime, let’s just hope the FDA’s highly anticipated regulations don’t go down the same path.

For a list of some of our earlier EU CBD posts, see:

The EU May Designate CBD Foods as “Narcotics” (Yes You Read that Right.) on Harris Bricken.


Today's Cannabis Investment Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.